Treating COVID-19 with Chloroquine

Mingxing Huang,Tiantian Tang,Pengfei Pang,Man Li,Ruolan Ma,Jiahui Lu,Jingxian Shu,Yingying You,Binghui Chen,Jiabi Liang,Zhongsi Hong,Huili Chen,Ling Kong,Dajiang Qin,Duanqing Pei,Jinyu Xia,Shanping Jiang,Hong Shan
DOI: https://doi.org/10.1093/jmcb/mjaa014
2020-04-01
Journal of Molecular Cell Biology
Abstract:A novel coronavirus disease 2019 (COVID-19) emerged around December 2019 in Wuhan, China and has spread rapidly worldwide (<a class="link link-ref link-reveal xref-bibr" href="">Lu et al., 2020</a>). Until March 27, 2020, the Chinese health authorities had reported 82082 confirmed COVID-19 cases in China with 3298 deaths and 381443 confirmed cases with 20787 deaths outside China. The World Health Organization (WHO) named the virus SARS-CoV-2, which belongs to a distinct clade from the human severe acute respiratory syndrome CoV (SARS-CoV) and Middle East respiratory syndrome CoV (MERS-CoV) (<a class="link link-ref link-reveal xref-bibr" href="">Zhu et al., 2020</a>). At present, there is no effective therapy against this new virus. Identifying effective antiviral agents to treat the COVID-19 is of most urgency.
cell biology
What problem does this paper attempt to address?